Posted on

cbd luxe sublingual spray review

Cbd luxe sublingual spray review

Rolling Stone is a part of Penske Media Corporation. © 2022 Rolling Stone, LLC. All Rights Reserved.

Verify it’s you

To help keep your account secure, please log-in again. Dismiss Log-In

Please log in

RS Live Media Logo Created with Sketch.

Cbd luxe sublingual spray review

A RCT available at ClinicalTrials.gov which investigated THC:CBD oromucosal spray (nabiximols) for relief of chronic refractory neuropathic pain due to MS or other defects of neurological function found a numerical but not statistically significant advantage in favor of active medication versus placebo for the change from baseline in the mean pain box scale-11 score (–1.3 vs –0.9; p = 0.33) after 3 weeks’ treatment (ClinicalTrials.gov identifier <"type":"clinical-trial","attrs":<"text":"NCT01606176","term_id":"NCT01606176">> NCT01606176). 90

A larger placebo-controlled trial of add-on THC:CBD oromucosal spray (nabiximols) conducted in 339 patients with refractory central neuropathic pain due to MS failed to meet the primary endpoint due to a high placebo response. After 14 weeks’ treatment, the proportion of patients with ≥30% NRS improvement was 50% and 45% in the THC:CBD spray (nabiximols) and placebo groups, respectively (p = 0.234). Likewise, the change from baseline in pain 0–10 NRS scores did not differ significantly between groups (–1.93 vs –1.76; p = 0.47). Among 58 patients who entered the 4-week randomized withdrawal phase, the primary endpoint of time to treatment failure significantly favored THC:CBD spray (nabiximols), with 24% of patients failing treatment compared with 57% of patients treated with placebo (p = 0.04). THC:CBD spray was generally well tolerated, with most adverse events judged as mild to moderate in severity. 89

A major contributing factor to the opioid epidemic in the US was increased opioid prescribing as part of a wider strategy to improve pain management, but ultimately leading to a dramatic increase in the number of prescription opioid overdose deaths. 25 Epidemiological data suggest that opioid misuse is also a concern in Europe. 26 – 28 In 2017, the six countries with the highest opioid consumption (reported as defined daily doses per million inhabitants per day) were, in order, the US, Germany, Canada, Austria, Belgium, and Switzerland. 28

Treatment of Chronic Cancer-Related Pain

The results of studies of THC:CBD spray (nabiximols) in patients with neuropathic pain of origins other than MS are mixed ( Table 2 ). 92 – 98

Use of herbal cannabis (smoked, vaporized, orally ingested), at present at least, is not suitable to manage pain or other medical conditions. Aside from practical issues such as restricted availability as regulated by national or regional health authorities, risks of herbal cannabis include variability in cannabinoid type and potency, potential for misuse/dependency, and possible future mental health-related consequences in young people. 57

Treatment of Chronic Neuropathic Pain

During clinical development of THC:CBD oromucosal spray (nabiximols) for MS spasticity, the most common treatment-related adverse events were mild to moderate transient episodes of dizziness, fatigue or somnolence. 38 , 78 Less commonly, mucosal irritation was reported. 38 To date, THC:CBD oromucosal spray (nabiximols) has not been associated with drug tolerance or a withdrawal syndrome 79 and there has been no evidence of drug misuse or abuse. 38 The estimated total post-marketing exposure of THC:CBD spray (nabiximols) at the end of 2018 was more than 120,000 patient-years. 80

The main limitations of studies reviewed herein are the short duration (for a chronic condition), heterogenous patient populations and lack of active comparators. Although the data set for THC:CBD oromucosal spray (nabiximols) in chronic pain includes two extension studies, only limited numbers of patients received treatment long term.

Spray desired amount under the tongue and hold for 90 seconds, then swallow.

TOPICAL USE

Contains 250 MG of CBD in heavy duty glass bottle with a specially designed atomizer that delivers a tiny nano size particulate mist for an effective sublingual uptake and topical coverage. Each spray delivers approximately 2 MG of pure 99.9% Pharma Grade CBD.

Studies have shown CBD to be an effective anti inflammatory (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828614/). It can be ingested or used topically. Our new specially designed spray top allows for fantastic skin coverage with just a tiny amount. It contains no artificial flavors colors or preservatives. In fact, with only 2 ingredients, Organic CBD and Organic MCT oil, it is perfect for those with sensitive skin or skin issues.

SUBLINGUAL USE

Sublingual use is an effective method for the uptake of CBD. Generally it takes up to 15 minutes to uptake CBD sublingually. While not as fast an uptake as vaping, sublingual use tends to last longer than vaping. And for those who don’t wish to inhale anything, sublingual use is a viable alternative uptake method.

Spray on affected area and rub in a circular direction until oil is fully absorbed.